Literature DB >> 19390215

Urinary fatty acids and liver-type fatty acid binding protein in diabetic nephropathy.

Hiroyo Sasaki1, Atsuko Kamijo-Ikemori, Takeshi Sugaya, Kayoko Yamashita, Takeshi Yokoyama, Jyunki Koike, Takeo Sato, Takashi Yasuda, Kenjiro Kimura.   

Abstract

BACKGROUND: The aims of this clinical study were to investigate the associations of urinary free fatty acid (FFA) levels with tubulointerstitial damage, and to determine the clinical significance of urinary liver-type fatty acid binding protein (L-FABP) in diabetic nephropathy.
METHODS: Fifteen patients with nephrotic syndrome due to diabetic nephropathy and 12 patients with minimal-change nephrotic syndrome (MCNS) were studied. Urinary and serum FFA concentrations (palmitic, oleic, linoleic, and arachidonic acids) were measured by gas chromatography, and urinary L-FABP levels were quantified using an ELISA technique. Tubulointerstitial damage was assessed using renal biopsy specimens.
RESULTS: The levels of urinary linoleic and arachidonic acids were significantly elevated in diabetic nephropathy compared to MCNS patients, though serum FFA levels were lower in diabetic nephropathy than MCNS patients. The degree of tubulointerstitial damage was significantly severer in the patients with diabetic nephropathy than MCNS. Urinary L-FABP and 8-OHdG (8-hydroxydeoxyguanosine) concentrations were significantly higher in the diabetic nephropathy subjects.
CONCLUSION: Elevated urinary excretion of FFA may be a reflection of FFA overload in the proximal tubules, and FFA may be an important promoter of tubulointerstitial damage in diabetic nephropathy patients. Urinary L-FABP levels may reflect the stress induced by FFA to the proximal tubules, leading to severe tubulointerstitial damage. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19390215     DOI: 10.1159/000214210

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  23 in total

Review 1.  The Role of Endoplasmic Reticulum Stress in Diabetic Nephropathy.

Authors:  Ying Fan; Kyung Lee; Niansong Wang; John Cijiang He
Journal:  Curr Diab Rep       Date:  2017-03       Impact factor: 4.810

Review 2.  Chronic kidney disease prediction is an inexact science: The concept of "progressors" and "nonprogressors".

Authors:  Macaulay Amechi Chukwukadibia Onuigbo; Nneoma Agbasi
Journal:  World J Nephrol       Date:  2014-08-06

3.  Liver fatty acid-binding protein as a diagnostic marker for non-alcoholic fatty liver disease.

Authors:  Erdem Akbal; Erdem Koçak; Ömer Akyürek; Seyfettin Köklü; Hikmetullah Batgi; Mehmet Şenes
Journal:  Wien Klin Wochenschr       Date:  2014-12-02       Impact factor: 1.704

4.  Hypoglycemia: A Possible Link between Insulin Resistance, Metabolic Dyslipidemia, and Heart and Kidney Disease (the Cardiorenal Syndrome).

Authors:  Myriam Ensling; William Steinmann; Adam Whaley-Connell
Journal:  Cardiorenal Med       Date:  2011-01-17       Impact factor: 2.041

Review 5.  Tubular atrophy in the pathogenesis of chronic kidney disease progression.

Authors:  Jeffrey R Schelling
Journal:  Pediatr Nephrol       Date:  2015-07-25       Impact factor: 3.714

6.  Protective effects of L-type fatty acid-binding protein (L-FABP) in proximal tubular cells against glomerular injury in anti-GBM antibody-mediated glomerulonephritis.

Authors:  Yasuhiko Kanaguchi; Yusuke Suzuki; Ken Osaki; Takeshi Sugaya; Satoshi Horikoshi; Yasuhiko Tomino
Journal:  Nephrol Dial Transplant       Date:  2011-04-27       Impact factor: 5.992

7.  Intrarenal renin-angiotensin system mediates fatty acid-induced ER stress in the kidney.

Authors:  Chunling Li; Yu Lin; Renfei Luo; Shaoming Chen; Feifei Wang; Peili Zheng; Moshe Levi; Tianxin Yang; Weidong Wang
Journal:  Am J Physiol Renal Physiol       Date:  2015-12-16

8.  Urinary Liver-Type Fatty Acid-Binding Protein Level as a Predictive Biomarker of Acute Kidney Injury in Patients with Acute Decompensated Heart Failure.

Authors:  Keiichi Hishikari; Hiroyuki Hikita; Shun Nakamura; Shun Nakagama; Masahumi Mizusawa; Tasuku Yamamoto; Junichi Doi; Yosuke Hayashi; Yuya Utsugi; Makoto Araki; Yuta Sudo; Shigeki Kimura; Atsushi Takahashi; Takashi Ashikaga; Mitsuaki Isobe
Journal:  Cardiorenal Med       Date:  2017-06-21       Impact factor: 2.041

9.  Renoprotection and the Bardoxolone Methyl Story - Is This the Right Way Forward? A Novel View of Renoprotection in CKD Trials: A New Classification Scheme for Renoprotective Agents.

Authors:  Macaulay Onuigbo
Journal:  Nephron Extra       Date:  2013-04-27

10.  Urinary liver-type fatty acid-binding protein and progression of diabetic nephropathy in type 1 diabetes.

Authors:  Nicolae M Panduru; Carol Forsblom; Markku Saraheimo; Lena Thorn; Angelika Bierhaus; Per M Humpert; Per-Henrik Groop
Journal:  Diabetes Care       Date:  2013-02-01       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.